Ferroportin inhibitors
VIT-2763
Update: 05 November 2020
No update available.
Update: 25 August 2020
- Data presented at the EHA Congress in June indicate that treatment with the oral ferroportin inhibitor VIT-2763 alone or in combination with DFX significantly increases haemoglobin.
Sources:
Update: 31 May 2020
- A phase 2 multiple dose, multicentre (USA & GR), double-blind, placebo-controlled parallel group study (VITHAL) in 36 adult and adolescent patients with NTDT is expected to start in June 2020.
- The study includes a 12-week treatment period and a safety follow-up period of 4 weeks.
Sources:
https://clinicaltrials.gov/ct2/show/NCT04364269?cond=Thalassemia&fund=2&draw=2&rank=3
https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002221-29/GR
Update: 31 March 2020
No update available.
Update: 31 January 2020
No update available.
Update: 25 November 2019
No update available.
Update: 27 September 2019
No update available
Update: 30 July 2019
Results announced during 24th Annual Congress of the European Hematology Association show that treatment with single and multiple oral doses of VIT-2763 were well tolerated in healthy subjects, decreasing the iron levels in circulation.
A proof of concept study in patients with β-thalassaemia is supported by these results.
Sources:
Update: 30 May 2019
No update available.
Update: 01 February 2019
A randomized, controlled, multi-centred phase 2 proof-of-concept trial will begin in the second half of 2019 to assess the effectiveness of the oral ferroportin inhibitor (VIT-2763) on iron overload in β-thalassaemia patients.
Phase 1 trials have shown positive results with a consistent lower serum iron for up to 24 hours post-dose. The results are dose-dependent.
Treatment with VIT-2763 can improve iron metabolism and the production of RBCs.
Sources: